(Reuters) - LONDON, July 3 - Irish drugmaker Elan Corp and U.S. partner Biogen Idec said on Tuesday that Britain's cost-effectiveness drugs panel had recommended their Tysabri drug to treat a severe form of multiple sclerosis.
The decision reverses a provisional ruling by Britain's National Institute for Health and Clinical Excellence and, assuming no successful appeal, will be ratified as guidance to the state-run National Health Service in August.
Read more at Reuters.com Government Filings News
The decision reverses a provisional ruling by Britain's National Institute for Health and Clinical Excellence and, assuming no successful appeal, will be ratified as guidance to the state-run National Health Service in August.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment